← Back to Clinical Trials
Recruiting NCT07193407

NCT07193407 INOPASE - Performance and Safety Study of a Personalised SNM System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07193407
Status Recruiting
Phase
Sponsor INOPASE Pty Ltd
Condition Overactive Bladder (OAB)
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2026-02-27
Primary Completion 2026-03-02

Trial Parameters

Condition Overactive Bladder (OAB)
Sponsor INOPASE Pty Ltd
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex FEMALE
Min Age 18 Years
Max Age 70 Years
Start Date 2026-02-27
Completion 2026-03-02
Interventions
Sacral Neuromodulation System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to learn whether a new sacral neuromodulation (SNM) system (INO-SNM-01) can safely and effectively sense bladder nerve activity and provide stimulation to help manage symptoms of refractory overactive bladder in adult women aged 18-70 who have not responded to standard treatments. The main questions it aims to answer are: * Is there a clear relationship between bladder nerve activity and patient-reported urgency sensations? * Can targeted stimulation based on bladder nerve activity reduce overactive bladder symptoms? * Is the INO-SNM-01 System safe to use? Researchers will not use a comparison group in this study. Instead, all participants will receive the investigational device to see if it works as intended. Participants will undergo surgery to have a temporary trial lead implanted near the sacral nerve and spend up to 2 days in hospital for monitoring and testing to assess the device sensing and stimulation capabilities. Up to 10 participants will take part in this first-in-human feasibility study at a single site in Australia.

Eligibility Criteria

Inclusion Criteria: * Adult female participants between 18 and 70 years of age * Diagnosed with refractory overactive bladder that is resistant to behavioural therapy and/or pharmacotherapy, for at least 12 weeks * Experience at least 3 urgency episodes within a 24-hour period from the past 3 consecutive days (reported in a bladder diary) * Baseline of greater than 7 on the Overactive Bladder Symptom Score (OABSS) * Baseline score of greater than 12 on the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules (ICIQ-FLUTS) * Willing to receive SNM therapy * Willing to provide free and Informed consent to participate in the clinical investigation * Able to understand all study instructions, willing to attend all study visits, and likely to comply with all study procedures Exclusion Criteria: * Participants who are diagnosed with stress urinary incontinence * Received tibial nerve stimulation therapy within the past 3 months * Received treatm

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology